Article Text

Download PDFPDF

Inhaled fluticasone in bronchiectasis: a 12 month study
Free
  1. K W Tsang1,
  2. K C Tan1,
  3. P L Ho2,
  4. G C Ooi2,
  5. J C Ho1,
  6. J Mak1,
  7. G L Tipoe3,
  8. C Ko1,
  9. C Yan1,
  10. W K Lam1,
  11. M Chan-Yeung1
  1. 1University Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong
  2. 2Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong
  3. 3Department of Anatomy, Queen Mary Hospital, The University of Hong Kong, Hong Kong
  1. Correspondence to:
    Professor K W T Tsang
    Department of Respiratory and Critical Care Medicine, University Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong; kwttsanghku.hk

Abstract

Background: The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation.

Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 μg twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion.

Results: 35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency ⩽2/year (p = 0.04), and sputum purulence score >5 (p = 0.03).

Conclusions: ICS treatment is beneficial to patients with bronchiectasis, particularly those with P aerurginosa infection.

  • bronchiectasis
  • fluticasone
  • inhaled corticosteroids

Statistics from Altmetric.com

Footnotes

  • This study was partially sponsored by GlaxoWelcome (Hong Kong).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.